AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04326036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liberase Enzyme (Roche)
Description: Sterile Collagenase Blend to separate cSVF from the AD-SVF
Study NCT04326036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liberase Enzyme (Roche)
Description: Sterile Collagenase Blend to separate cSVF from the AD-SVF
Study NCT04326036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline for Intravenous Use
Description: Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
Study NCT04326036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sterile Normal Saline for Intravenous Use
Description: Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
Study NCT03001700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serranator™ Alto PTA Serration Balloon Catheter
Description: The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
Study NCT03564106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular methylprednisolone
Description: intraarticular methylprednisolone (30 mg)
Study NCT01955499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01955499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT01955499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT01955499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT
Study NCT01955499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03938285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theranova 400 membrane
Description: Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Study NCT03938285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FxCordiax 120 membrane
Description: Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Study NCT01144715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Mentor (TM) robotic stroke therapy device
Description: The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
Study NCT01144715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Therapy Program
Description: Subjects in the control group will be instructed in a self administered home therapy program
Study NCT03106987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator: Olaparib tablets
Description: Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Study NCT03106987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Study NCT03035929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A single dose of dexamethasone IV 4 mg will be administered.
Study NCT02914860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: * Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map.
Study NCT02428660 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
Study NCT02428660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software-based drug & gene interaction risk analysis
Description: By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
Study NCT02428660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Software-based drug & gene interaction risk analysis
Description: By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
Study NCT02428660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MTM
Description: Medication Therapy Management
Study NCT02428660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTM
Description: Medication Therapy Management
Study NCT02612792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Open flap debridement (OFD) alone
Study NCT02612792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
Study NCT02428660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTM
Description: Medication Therapy Management
Study NCT02278263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Given intravenously or topically
Study NCT01047800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions.
Study NCT02897752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait training with WA
Description: Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
Study NCT02897752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual gait training
Description: Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
Study NCT04798742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gluteus maximus transfer
Description: Gait analysis study of 15 patients with gluteus medius disruption
Study NCT02452853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR
Description: HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
Study NCT02612792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
Study NCT00364611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses
Study NCT02452853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks
Study NCT00364611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
Study NCT00364611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: * A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion
Study NCT03244189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid prescription
Description: The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
Study NCT02278263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% NaCl)
Description: Administered in all 3 groups
Study NCT02278263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% NaCl)
Description: Administered in all 3 groups
Study NCT03244189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
Study NCT03244189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Problem Solving
Description: Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
Study NCT02862028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HerinCAR-PD1 cells
Description: herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
Study NCT04214106 — intervention group
Intervention type: DRUG
Intervention: intravenous Thiamine
Description: patients who received Thiamine,100-500 mg/day for at least one day
Study NCT02108795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
Study NCT02108795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00883792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Once-only colonoscopy screening
Study NCT03411356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Caloric Restriction (DCR)
Description: Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
Study NCT03411356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IMF)
Description: Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
Study NCT03018470 — intervention group
Intervention type: OTHER
Intervention: Analysis of data from NIV built-in software
Description: Analysis of breathing pattern using data obtained from NIV built-in software
Study NCT01008228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exsufflation
Description: exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
Study NCT01008228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic tube drainage
Description: thoracic tube drainage will be performed with a tube Ch 16 or ch 20
Study NCT02227589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET/CBT-12
Description: Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
Study NCT02227589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT-12
Description: Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
Study NCT00839865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herb ointment
Description: a kind of ointment made from herb
Study NCT05778773 — intervention group
Intervention type: PROCEDURE
Intervention: TAVR (Transcatheter Aortic Valve Replacement)
Description: Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
Study NCT01714336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
Study NCT01714336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
Study NCT04433936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam tomography
Description: The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
Study NCT03553264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation
Description: Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
Study NCT03553264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
Study NCT03553264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
Study NCT01631006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: A low or high CPAP pressure is delivered for 20 minutes
Study NCT01631006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: A low or high CPAP pressure is delivered for 20 minutes
Study NCT01363154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mozart K448
Description: Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
Study NCT01363154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beethoven's Für Elise
Description: Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
Study NCT01363154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No music exposure
Description: Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
Study NCT03042728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog Interaction
Description: A therapy dog will visit the patients.
Study NCT03042728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Interaction
Description: A human will visit the patients.
Study NCT03763292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific information brochure
Description: A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
Study NCT02227589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-D
Description: CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
Study NCT05778773 — intervention group
Intervention type: PROCEDURE
Intervention: AVR (Aortic Valve Replacement)
Description: Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
Study NCT02914860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: * Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map.
Study NCT02914860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Procedure
Description: 1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia.